Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Triple-negative breast cancer remains a formidable clinical challenge owing to its immunosuppressive microenvironment and inherently low immunogenicity. Methods To address this, we developed a multifunctional Pickering emulsion (Fe-PDA-PE-R837) stabilized by iron-doped polydopamine (Fe-PDA) nanoparticles, which function dually as photothermal agents and localized iron donors, while the soybean oil core encapsulates the immunoadjuvant R837. The Fe-PDA nanoparticles exhibited uniform spherical morphology, excellent colloidal stability, and a broad absorption band extending to the NIR region. Upon 808 nm laser irradiation, the Fe-PDA shell generates local hyperthermia with a photothermal conversion efficiency of 38.5%, disrupts intracellular iron homeostasis to provoke ferroptotic cell death, as evidenced by GSH depletion and MDA accumulation, while the stimuli-responsive release of R837 coupled with immunogenic cell death (ICD) elicits potent local and systemic pro-inflammatory responses. Results In vitro assays demonstrated that the combination treatment achieved ∼80% cell killing, markedly inhibited cell migration, and significantly upregulated TNF-α and IL-12 secretion. In vivo evaluation using the 4T1 murine breast cancer model confirmed that this nanoplatform significantly suppressed primary tumor growth and pulmonary metastasis, with no appreciable systemic toxicity. Discussion Collectively, this interfacial engineering strategy underscores the promising translational potential of Pickering emulsion-based nanoplatforms for aggressive solid tumor therapy.